CD19 and B-cell non-Hodgkin lymphoma: Axicabtagene ciloleucel, the second FDA-approved autologous CD19 CAR-T therapy, was applied to large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and Follicular lymphoma (FL)-transformed DLBCL based on a multicenter ZUMA-1 trial.